Updates are available Correction dated 2022-10-07
Click to view Correction: https://doi.org/10.1038/s41409-022-01834-z
-
Authors
Nagler, Arnon https://orcid.org/0000-0002-0763-1265
Peczynski, Christophe https://orcid.org/0000-0002-3829-0088
Dholaria, Bhagirathbhai https://orcid.org/0000-0003-2371-3655
Labopin, Myriam https://orcid.org/0000-0003-4514-4748
Valerius, Thomas
Dreger, Peter https://orcid.org/0000-0002-7429-8570
Kröger, Nicolaus
Reinhardt, Hans Christian
Finke, Jürgen
Franke, Georg-Nikolaus https://orcid.org/0000-0001-8239-002X
Ciceri, Fabio https://orcid.org/0000-0003-0873-0123
Verbeek, Mareike
Blau, Igor Wolfgang
Bornhäuser, Martin
Spyridonidis, Alexandros https://orcid.org/0000-0003-3097-2532
Bug, Gesine https://orcid.org/0000-0003-2359-131X
Bazarbachi, Ali https://orcid.org/0000-0002-7171-4997
Schmid, Christophe https://orcid.org/0000-0001-7070-487X
Yakoub-Agha, Ibrahim
Savani, Bipin N.
Mohty, Mohamad https://orcid.org/0000-0002-7264-808X
- License Information
-
More Information
Article History
Received: 29 December 2021
Revised: 19 April 2022
Accepted: 21 April 2022
First Online: 30 April 2022
Change Date: 7 October 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41409-022-01834-z
Competing interests
: HCR received consulting and lecture fees from Abbvie, AstraZeneca, Vertex and Merck. HCR received research funding from Gilead Pharmaceuticals. HCR is a co-founder of CDL Therapeutics GmbH. BD reported Institutional research funding: Takeda, Janssen, Angiocrine, Pfizer, Poseida, MEI, Sorrento. Consultancy: Jazz, Gamida Cell, MJH BioScience The remaining authors report no relevant conflict of interest concerning this work.
